Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Schmitt
S
S
University of Heidelberg, Dept. of Medicine V (Hematology/Oncology/Rheumatology), Heidelberg, Germany.
Bertsch
U
U
Goldschmidt
H
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib